SU
Supriya Lifescience Limited
SUPRIYA.NS · NSE
₹904.40 -1.42% (-₹13.05)
1M +13.91%
Market Cap ₹67.9B
P/E Ratio 34.21x
Div. Yield 0.12%
ROE 18.21%
Bulios Fair Price
₹645.81
28.6% downside
Trenutna cena
₹904.4
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica SUPRIYA.NS trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
5/9Valuation
21 /100
Expensive PEG 0.62x
P/E 34.21x
P/B 5.67x
Growth
65 /100
Stable Book val. growth 17.42%
EPS growth 7.38%
Rev. growth 10.28%
Profitability
75 /100
Strong Op. margin 37.47%
Gross margin 64.36%
FCF margin 1.52%
Quality
88 /100
Excellent ROA 14.62%
ROIC 19.62%
Asset turnover 0.64x
Debt
100 /100
Low Int. coverage 196.01x
Debt/Equity 0.00x
Net debt/EBITDA -0.25x
Stability
66 /100
Moderate EPS volatility 51.23%
Beta 0.65x
Profitable years 6
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SUPRIYA.NS
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Satish Waman Wagh
Employees
521
Headquarters
Mumbai
Prihajajoči dogodki
11 NOV.
Earnings
Upcoming earnings report